El interés en corto de Aptorum Gr da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Aptorum Gr. Los datos de interés en corto se actualizan cada dos semanas.

Aptorum Gr (NASDAQ:APM) Bolsa, Informe de interés en corto

Aptorum Gr

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

apM Coin

MORIEN RESOURCES CORP ORD by Morien Resources Corp.

Morien Resources Corp

EAGLE GRAPHITE INC by Eagle Graphite Inc.

APM HUMAN SVCS INTL PTY by APM HUMAN SVCS INTL PTY LTD.

ApartmentLove Inc

ASPERMONT LTD by ASPERMONT LTD.

Amper SA

Aperam SA

Trust for Professional Managers ActivePassive Intermediate Municipal Bond ETF

<p>Citius Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 12,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of its common stock, at a purchase price of $0.25 per share and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.25 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date.&nbsp; The closing of the offering is expected to occur on or about November 18, 2024, subject to the satisfaction of customary closing conditions.</p>
<p>H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</p>
<p>The aggregate gross proceeds to the Company from the offering are expected to be $3 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.</p>


News

Offerings

CTXR

Citius Pharmaceuticals Entered Into Definitive Agreements For The Purchase Of An Aggregate Of 12M Shares Of Its Common Stock And Accompanying Warrants To Purchase Up To An Aggregate Of 12M Shares Of Its Common Stock, At A Purchase Price Of $0.25 Per Share And Accompanying Warrant In A $3M Registered Direct Offering

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Expedia Group</strong>.</p>
<p>Looking at options history for Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $203,880 and 6, calls, for a total amount of $424,321.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $192.5 for Expedia Group over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Expedia Group stands at 475.71, with a total volume reaching 1,784.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Expedia Group, situated within the strike price corridor from $110.0 to $192.5, throughout the last 30 days.</p>
<h3>Expedia Group Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731695489_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$21.5</td>
<td>$21.1</td>
<td>$21.5</td>
<td>$160.00</td>
<td>$107.6K</td>
<td>1.3K</td>
<td>151</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.95</td>
<td>$21.0</td>
<td>$21.28</td>
<td>$160.00</td>
<td>$106.4K</td>
<td>1.3K</td>
<td>51</td>
</tr>
<tr>
<td>EXPE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$1.43</td>
<td>$0.72</td>
<td>$0.74</td>
<td>$172.50</td>
<td>$88.8K</td>
<td>54</td>
<td>1.2K</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$21.3</td>
<td>$21.05</td>
<td>$21.3</td>
<td>$160.00</td>
<td>$78.8K</td>
<td>1.3K</td>
<td>101</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$41.75</td>
<td>$40.25</td>
<td>$40.81</td>
<td>$140.00</td>
<td>$65.2K</td>
<td>1.3K</td>
<td>16</td>
</tr>
</tbody>
</table>
</p>
<h3>About Expedia Group</h3>
<p>Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2023 sales), air tickets (3%), rental cars, cruises, in-destination, and other (11%), and advertising revenue (6%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.</p>
<p>Having examined the options trading patterns of Expedia Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Expedia Group</h3>
<ul>
<li>With a volume of 719,408, the price of EXPE is down -1.06% at $180.33. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>Expert Opinions on Expedia Group</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $173.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Expedia Group, targeting a price of $210.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Expedia Group, targeting a price of $166.<br />
&#x2A; An analyst from Jefferies persists with their Hold rating on Expedia Group, maintaining a target price of $160.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Expedia Group with a target price of $153.<br />
&#x2A; An analyst from Wedbush persists with their Neutral rating on Expedia Group, maintaining a target price of $180. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Expedia Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

EXPE

Expedia Group Options Trading: A Deep Dive into Market Sentiment

<p>Compass Point  analyst Casey Alexander   maintains Blackstone Secured (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXSL#NYSE">BXSL</a>) with a Buy and lowers the price target from $33.5 to $32.25.</p>


Price Target

Analyst Ratings

BXSL

Compass Point Maintains Buy on Blackstone Secured, Lowers Price Target to $32.25

<p>High-rolling investors have positioned themselves bullish on Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CHTR often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 14 options trades for Charter Communications. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 35% bullish and 7% bearish. Among all the options we identified, there was one put, amounting to $36,400, and 13 calls, totaling $389,626.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $130.0 and $400.0 for Charter Communications, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Charter Communications's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Charter Communications's substantial trades, within a strike price spectrum from $130.0 to $400.0 over the preceding 30 days.</p>
<h3>Charter Communications Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731695484_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$152.6</td>
<td>$151.3</td>
<td>$151.3</td>
<td>$300.00</td>
<td>$75.6K</td>
<td align="right">722</td>
<td align="right">12</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$75.0</td>
<td>$72.8</td>
<td>$72.8</td>
<td>$400.00</td>
<td>$36.4K</td>
<td align="right">918</td>
<td align="right">12</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$265.8</td>
<td>$257.7</td>
<td>$262.21</td>
<td>$130.00</td>
<td>$26.2K</td>
<td align="right">0</td>
<td align="right">13</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$264.8</td>
<td>$257.6</td>
<td>$262.21</td>
<td>$130.00</td>
<td>$26.2K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$262.5</td>
<td>$257.7</td>
<td>$262.15</td>
<td>$130.00</td>
<td>$26.2K</td>
<td align="right">0</td>
<td align="right">18</td>
</tr>
</tbody>
</table>
</p>
<h3>About Charter Communications</h3>
<p>Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 58 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.</p>
<p>In light of the recent options history for Charter Communications, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Charter Communications's Current Market Status</h3>
<ul>
<li>With a volume of 452,368, the price of CHTR is down -0.95% at $390.52. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Charter Communications</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $386.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Charter Communications, targeting a price of $400.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Underweight rating on Charter Communications with a target price of $315.<br />
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Charter Communications, maintaining a target price of $400.<br />
&#x2A; Showing optimism, an analyst from B of A Securities upgrades its rating to Buy with a revised price target of $450.<br />
&#x2A; An analyst from Deutsche Bank persists with their Hold rating on Charter Communications, maintaining a target price of $365. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Charter Communications options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


CHTR

Spotlight on Charter Communications: Analyzing the Surge in Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CPRI usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Capri Holdings. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 7 are puts, totaling $238,026, and 3 are calls, amounting to $132,484.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $42.5 for Capri Holdings over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Capri Holdings options trades today is 1805.0 with a total volume of 1,847.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Capri Holdings's big money trades within a strike price range of $15.0 to $42.5 over the last 30 days.</p>
<h3>Capri Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731695479_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$19.8</td>
<td>$19.2</td>
<td>$19.4</td>
<td>$40.00</td>
<td>$64.0K</td>
<td>10.3K</td>
<td align="right">35</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.4</td>
<td>$1.25</td>
<td>$1.4</td>
<td>$20.00</td>
<td>$55.7K</td>
<td>1.7K</td>
<td align="right">436</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$15.00</td>
<td>$46.2K</td>
<td>96</td>
<td align="right">70</td>
</tr>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.3</td>
<td>$21.4</td>
<td>$21.94</td>
<td>$42.50</td>
<td>$32.9K</td>
<td>75</td>
<td align="right">15</td>
</tr>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.5</td>
<td>$17.1</td>
<td>$17.22</td>
<td>$37.50</td>
<td>$30.9K</td>
<td>121</td>
<td align="right">33</td>
</tr>
</tbody>
</table>
</p>
<h3>About Capri Holdings</h3>
<p>Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.</p>
<p>Following our analysis of the options activities associated with Capri Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>Capri Holdings's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,261,855, the CPRI's price is up by 0.85%, now at $20.7. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What The Experts Say On Capri Holdings</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $27.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo downgraded its action to Equal-Weight with a price target of $42.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Capri Holdings, which currently sits at a price target of $22.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Capri Holdings, targeting a price of $23.<br />
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Market Perform rating on Capri Holdings with a target price of $26.<br />
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Capri Holdings, targeting a price of $23. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Capri Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CPRI

Market Whales and Their Recent Bets on CPRI Options

<p><strong>Tesla Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) analysts Tom Narayan and Brad Erickson highlight the company's potential with FSD and robotaxis and also share thoughts on whether the electric vehicle giant could work with <strong>Uber Technologies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and<strong> Lyft Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) instead of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41295072/tesla-robotaxi-day-event-more-fanfare-than-substance-8-analysts-on-cybercab-optimus">competing against them.</a></p>
<p><strong>Tesla FSD, Autonomous Opportunity:</strong> RBC hosted investors at Tesla's Giga Texas facility and now has "increasing confidence" in the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41259841/uber-vs-tesla-maybe-not-analysts-say-autonomous-vehicles-will-be-market-expanding">company's autonomous vehicle goals</a>, along with more confidence in seeing the company's competitive advantages in manufacturing over other automotive companies.</p>
<p>Narayan and Erickson, who have an Outperform rating on Tesla, raised the price target from $249 to $313.</p>
<p>"While we think much of the stock's post-election share price move is not rooted in fundamentals, we like the risk/reward of our implied upside value/share versus our downside," the analysts said.</p>
<p>The analysts said the automotive sector remains challenging and Tesla stock could see near-term pressure, but has a chance for long-term growth thanks to FSD innovation. The analysts assign a value of $102 per share for Tesla's FSD business, cars represent $36 per share and robotaxis represent $136 per share.</p>
<p><span style="box-sizing: border-box; margin: 0px; padding: 0px;">The analysts said</span> <strong>Donald Trump</strong>&#8216;s elimination of the electric vehicle credit could be a net negative for Tesla, which is expected to gain market share as a result.</p>
<p>Tesla's newest version of FSD includes a "hands-off" allowance for roads in the United States, which could put Tesla ahead of other competitors, the analysts said.</p>
<p>"Almost every OEM L2+ product in the market currently has limitations. Most do not take exits, make turns, and in some cases do automatic lane changes."</p>
<p>The analysts expect FSD pricing to come down to $50 per month for consumers, but see the future opportunity to increase the price to $100 per month with new features.</p>
<p>Tesla could earn $83 billion in revenue from FSD and could see $22 billion in licensing revenue for the software by 2035, the analysts said.</p>
<p>The analysts see FSD's value rising from $61 per share to $102 per share, representing 33% of the overall price target on Tesla and 64% of the price target increase.</p>
<p>RBC's tour of Giga Texas also led to a price increase on Tesla cars, thanks to the company's vertical integration and cost structure advantages over the competition.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">Tesla Q3 Earnings Highlights: EPS Beat, Revenue Miss, Shares Climb On 2025 Timeline For Lower-Cost EVs</a></strong></p>
<p><strong>Robotaxi Opportunity: </strong>The analysts said Tesla is committed to owning all pieces of the robotaxi ecosystem, which includes the vehicle, software and app. This could give the company a competitive cost advantage over other autonomous vehicles, the analysts added.</p>
<p>Narayan and Erickson think Tesla could represent a 20% share of robotaxis in the U.S., 6% in Europe, and 8% in China.</p>
<p>While Tesla robotaxis could be bad news for ride-hail companies like Uber and Lyft, the analysts see an opportunity for the market size to grow and for potential partnerships.</p>
<p>"Ride volumes would increase dramatically, helped by lower pricing coming from AV ridesharing," the analysts said. "Currently, only 1% of miles driven in the U.S. for example, come from ridesharing."</p>
<p>Tesla has around two million vehicles on the road in the US and Uber has 70 million to 80 million active users, the analysts noted.</p>
<p>"As such, partnering with Uber makes sense to expand its customer base."</p>
<p>Erickson said he has "rising conviction" that Tesla could be more open to working with Uber and Lyft at some point.</p>
<p>"We believe the successful AV networks of the future will involve deeply integrated partnerships composed of OEMs, suppliers, software-enablers and ride-hailing networks all playing their critical roles in delivering a safe, reliable and, importantly, economically sustainable service."</p>
<p>Erickson said Uber and Lyft are likely to benefit from a growing total addressable market expansion for ride-hail and robotaxis with or without a partnership from Tesla.</p>
<p>"We believe Tesla is more mindful of maintaining some level of economic rationality than we might have thought previously and would view them more as a partnership candidate over time."</p>
<p>Without partnerships with Lyft and Uber, Tesla could have to spend tens of billions of dollars to reach "adequate marketplace density and liquidity."</p>
<p>RBC has an Outperform rating on Lyft with a $24 price target. RBC has an Outperform rating on Uber with an $82 price target.</p>
<p><strong>TSLA, UBER, LYFT Price Action:</strong> Tesla stock is up 3% to $320.41 on Friday versus a 52-week trading range of $138.80 to $358.64. Tesla stock is up 29% year-to-date.</p>
<p>Uber stock is up 2% to $73.00 on Friday versus a 52-week trading range of $53.15 to $87.00. Uber stock is up 25% year-to-date.</p>
<p>Lyft stock is up 1% to $18.02 on Friday versus a 52-week trading range of $8.92 to $20.82. Lyft stock is up 31% year-to-date.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this">If Tesla Stock Hits All-Time Highs In 2025, Will It Be Driven By Trump-Musk Relationship? Benzinga Readers Say This</a></strong></li>
</ul>
<p><em>Image created using artificial intelligence via Midjourney.</em></p>


Analyst Color

Reiteration

Trading Ideas

LYFT

TSLA

UBER

Tesla To Partner With Lyft, Uber? Analyst Has 'Rising Conviction' For Future Partnership

<p><strong>Tilray Brands Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) faces a new shareholder lawsuit accusing the Canadian cannabis company of misleading voting practices for a second consecutive year. </p>
<p>The legal complaint, filed on October 31, 2024 in the Delaware Court of Chancery, alleges that Tilray misled investors regarding the voting requirements to increase its authorized shares, <a href="https://www.investing.com/news/company-news/tilray-faces-shareholder-lawsuit-over-voting-standards-93CH-3707585">reported</a> Investing.com.</p>
<h3 class="wp-block-heading"><strong>Disputed Voting Standards And Shareholder Allegations</strong></h3>
<p>According to the lawsuit, Tilray's proxy statements for the 2023 and 2024 annual meetings inaccurately presented the voting standards needed for approval. The plaintiff argues that the company required only a majority of votes cast, rather than a majority of all outstanding shares, to pass proposals that increased the number of authorized shares. This discrepancy, the complaint claims, invalidates the approval and subsequent issuances of new common stock.</p>
<p>The lawsuit contends that Tilray's board of directors breached their fiduciary duties by failing to provide accurate information.</p>
<p>The plaintiff seeks to block the company from holding a vote on the 2024 Authorized Shares Proposal at the upcoming annual meeting <strong>scheduled for November 21, 2024</strong>. Additionally, the lawsuit demands reimbursement of legal fees and related costs for the affected shareholders.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41997646/tilray-joins-german-cannabis-fiesta-with-first-locally-grown-strains">Tilray Joins German Cannabis Fiesta With First Locally Grown Strains</a></strong></p>
<p><em><strong>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</strong></em></p>
<h3 class="wp-block-heading"><strong>Tilray's Defense And Institutional Support</strong></h3>
<p>Tilray, however, firmly denies the allegations, stating that its voting practices comply with the 2023 amendments to Delaware's General Corporation Law. </p>
<p>The company maintains that the lower threshold for stockholder approval aligns with legal standards for corporations listed on national exchanges. Tilray's management argues that the increase in authorized shares is necessary for enhancing financial flexibility and facilitating strategic acquisitions.</p>
<p>Institutional Shareholder Services (ISS) has endorsed Tilray's proposal, recommending shareholders vote in favor of the increase, citing no significant concerns over past share usage.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41273594/tilray-reports-200m-q1-net-revenue-up-13-yoy-as-net-loss-improves">Tilray Reports $200M Q1 Net Revenue, Up 13% YoY As Net Loss Improves</a></strong></li>
</ul>
<p><em>Cover: AI generated image</em></p>


Cannabis

Legal

TLRY

Shareholder Lawsuit Challenges Tilray's Voting Tactics For Authorized Share Increase

<p><a href="https://www.bloomberg.com/news/articles/2024-11-15/lucid-ceo-says-unprofitable-ev-maker-is-immune-from-trump-policy-changes">https://www.bloomberg.com/news/articles/2024-11-15/lucid-ceo-says-unprofitable-ev-maker-is-immune-from-trump-policy-changes</a></p>
<p>Lucid Group Inc.'s chief executive downplayed the significance of US electric vehicle tax credits for the company, even as concerns about the potential loss of subsidies sent the EV maker's shares to new lows.</p>


LCID

Reported Earlier, 'Lucid CEO Says EV Maker Mostly Immune If Trump Nixes Tax Credit' - Bloomberg News

<p>BTIG  analyst Gregory Lewis   maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $15 to $19.</p>


Core Scientific, Inc. - Class A Common Stock

CORZ

BTIG Maintains Buy on Core Scientific, Raises Price Target to $19

WIIM

McDonalds shares are trading lower after the company announced it will spend $100 million to move past the E. Coli outbreak it experienced at some of its stores.

<p>BTIG  analyst Gregory Lewis   maintains Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Buy and raises the price target from $6 to $9.</p>


CIFR

BTIG Maintains Buy on Cipher Mining, Raises Price Target to $9

<p>The U.S. Treasury Department has released its <a href="https://www.fincen.gov/frequently-requested-foia-processed-records">quarterly report</a>, revealing that last year, over 830 financial institutions nationwide have officially acknowledged relationships with state-licensed cannabis businesses. According to a <a href="https://norml.org/news/2024/11/14/treasury-report-over-800-banking-institutions-report-relationships-with-state-licensed-cannabis-businesses/?link_id=5&amp;can_id=23ddea46021350bb8012464da757f45b&amp;source=email-norml-news-of-the-week-11142024&amp;email_referrer=email_2530540&amp;email_subject=norml-news-of-the-week-11142024">report</a> from the <strong>National Organization for the Reform of Marijuana Laws (NORML)</strong>, this number reflects a modest increase from the previous year and represents nearly double the number of banks and credit unions engaged with the cannabis sector in 2018.</p>
<p>However, despite this growth, fewer than 10% of all financial institutions in the U.S. currently provide services to the <a href="https://www.benzinga.com/cannabis">cannabis industry</a>. The ongoing hesitation among banks stems from federal law, which classifies marijuana as a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I controlled substance</a>. This classification poses significant legal risks for banks, even when working with businesses fully compliant with state cannabis regulations.</p>
<h3 class="wp-block-heading"><strong>Legislative Stalemate Continues To Hinder Progress</strong></h3>
<p>Efforts to resolve the banking issue have <a href="https://www.benzinga.com/markets/cannabis/24/07/39730510/house-gop-divided-over-cannabis-strikes-banking-protections-from-bill-respect-the-will-of-these-">repeatedly stalled in Congress</a>. The U.S. House of Representatives has passed legislation seven times to <a href="https://www.benzinga.com/topic/secure-and-fair-enforcement-safe-banking-act">protect financial institutions</a> that serve cannabis businesses from federal penalties. Yet, the Senate has <a href="https://www.benzinga.com/markets/cannabis/24/06/39324658/gop-controlled-house-strips-cannabis-banking-protections-from-government-spending-bill-in-blow-t">failed to advance</a> these proposals to a floor vote, leaving the cannabis industry in a precarious financial position.</p>
<p>The lack of clear federal guidelines continues to deter many banks, exacerbating the challenges faced by cannabis businesses in securing banking services and investment capital. According to a survey by Whitney Economics, <a href="https://www.benzinga.com/markets/cannabis/22/01/25324529/survey-72-of-cannabis-operators-say-lack-of-banking-is-biggest-problem-even-fewer-are-making-pro">over 70% of cannabis operators</a> cited limited access to banking and capital as their primary obstacle.</p>
<h3 class="wp-block-heading"><strong>Impact On Smaller And Minority-Owned Businesses</strong></h3>
<p>The absence of comprehensive banking reform disproportionately impacts smaller and minority-owned cannabis businesses, which often rely on traditional financing to grow and operate. NORML, the first cannabis advocacy group in U.S., has called on Congress to amend federal banking laws. "No industry can operate safely, transparently, or effectively without access to banks or other financial institutions. The players in this industry, particularly smaller and minority-owned businesses, and their consumers will remain severely hampered without better access to credit and financing," said NORML deputy director <strong>Paul Armentano</strong>.</p>
<p>The lack of federal legalization and banking access for cannabis has <a href="https://www.benzinga.com/markets/cannabis/23/04/31671933/is-the-cannabis-industry-ignoring-minority-communities">disproportionately impacted minorities</a> and small businesses. Many entrepreneurs, especially from marginalized communities, face significant barriers to entry in the cannabis industry due to limited access to financial services, such as loans and credit. This forces many to operate in cash, increasing risks and operational difficulties. Additionally, the continued federal prohibition contributes to <a href="https://www.benzinga.com/markets/cannabis/22/08/28566915/racism-blossoms-in-states-with-criminal-penalties-for-cannabis-possession">racial disparities in arrests</a> and convictions related to cannabis, even as legalization spreads at the state level. Without full legalization and banking reform, these barriers hinder economic opportunities for minority business owners and perpetuate systemic inequities.</p>
<h3 class="wp-block-heading"><strong>The Path Forward: SAFER Banking Act</strong></h3>
<p>The <a href="https://www.benzinga.com/topic/safer-banking-act"><strong>SAFER Banking Act</strong></a> remains a key focus for cannabis advocates, who argue that it would provide the much-needed clarity and legal protection for financial institutions willing to work with the industry. The bill&#8217;s future remains tied to the broader <a href="https://www.benzinga.com/topic/cannabis-rescheduling">debate over federal cannabis policy</a>, and advocates <a href="https://www.benzinga.com/markets/cannabis/24/10/41133218/house-democrats-urge-dea-to-speed-up-cannabis-rescheduling">continue to push for its passage</a> to ensure safer, more equitable conditions for cannabis businesses across the U.S. For now, the limited participation of banks underscores the persistent legal uncertainty surrounding cannabis, even as the industry continues to expand across state markets.</p>
<p><em>Cover image made with AI</em></p>


Treasury Report: Over 800 Banks Partnered With Cannabis Companies In 2023 Despite Federal Hurdles

<p>BTIG  analyst Gregory Lewis   maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Buy and raises the price target from $16 to $20.</p>


BTIG Maintains Buy on Bloom Energy, Raises Price Target to $20

<p><strong>Meta Platforms Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) plans to challenge recent court decisions that allow several states and hundreds of school districts across the United States to proceed with lawsuits.</p>
<p>These legal actions accuse Meta's <a target="_blank" href="https://www.benzinga.com/news/24/10/41349398/mark-zuckerbergs-meta-to-face-lawsuits-over-teen-social-media-addiction-judge-rejects-dismissal-moti" rel="noreferrer noopener">social media platforms</a>, including Facebook and Instagram, of contributing to a mental health crisis among young users.</p>
<p>The company filed appeals late Thursday, seeking a review by the U.S. Ninth Circuit Court of Appeals.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41981957/meta-hit-with-841-million-eu-fine-over-antitrust-violations-tied-to-facebook-marketplace" rel="noreferrer noopener">Meta Hit With $841 Million EU Fine Over Antitrust Violations Tied To Facebook Marketplace</a></em></p>
<p>The appeals follow separate rulings by a federal judge in California last month, which rejected Meta's requests to dismiss the lawsuits, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-15/meta-to-appeal-orders-letting-schools-states-sue-over-addiction?srnd=homepage-Americas&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.</p>
<p>U.S. District Judge Yvonne Gonzalez Rogers ruled in favor of 34 state attorneys general who argued that Meta's social media platforms, Facebook and Instagram, have had detrimental effects on youth mental health, leading to claims of negligence and public harm.</p>
<p>However, Judge Rogers largely denied motions to dismiss negligence claims but limited specific allegations, referencing Section 230 of the Communications Decency Act.</p>
<p>Alongside Meta, other tech giants such as <strong>Snap Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) and <strong>Alphabet Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) were also named in lawsuits filed by various school districts.</p>
<p><strong>TikTok</strong>&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/10/41243023/tiktok-gets-sued-13-states-and-dc-accuse-chinese-platform-of-boosting-corporate-profits-via-social-m" rel="noreferrer noopener">faces regulatory action</a> from&nbsp;13 U.S. states and the&nbsp;District of Columbia for allegedly harming the youth.</p>
<p>Meta's legal team is moving forward with the appeal. The company argues that its platforms are not directly responsible for the alleged mental health issues, citing protections under existing internet laws.</p>
<p>Meta, Snap, and TikTok jointly launched Thrive to <a target="_blank" href="https://www.benzinga.com/news/24/09/40846628/meta-snap-and-tiktok-come-together-to-combat-suicide-and-self-harm-content-online-will-share-signals" rel="noreferrer noopener">tackle the spread</a> of harmful content related to self-harm and suicide on their platforms.</p>
<p>The program enables these social media companies to share alerts about graphic content, enhancing efforts to limit its reach.</p>
<p>The Mental Health Coalition collaborates with companies to help address concerns and reduce the stigma around mental health issues online.</p>
<p>Meta reported removing over 12 million posts related to suicide and self-harm on Facebook and Instagram between April and June this year.</p>
<p>Recently, <a target="_blank" href="https://www.benzinga.com/general/social-media/24/11/41862616/meta-ceo-mark-zuckerberg-dodges-personal-liability-in-child-social-media-addiction-lawsuits-federal-judge-cites-lack-of-evidence" rel="noreferrer noopener">Rogers ruled</a> that Meta CEO Mark Zuckerberg is not personally liable in 25 lawsuits alleging social media addiction among children.</p>
<p>Judge Yvonne Gonzalez Rogers dismissed claims suggesting Zuckerberg ignored internal warnings about mental health risks on Facebook and Instagram.</p>
<p>The plaintiffs argued that Zuckerberg downplayed the dangers, but the judge cited insufficient evidence of his direct involvement.</p>
<p>The ruling only applies to claims against Zuckerberg, while similar legal challenges against Meta remain unaffected.</p>
<p><strong>Price Action:</strong> META stock is down 3.73% at $555.66 at the last check on Friday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/tech/24/11/41978712/asml-projects-revenue-surge-to-63-billion-by-2030-eyes-ai-and-chip-market-boom" target="_blank" rel="noreferrer noopener">ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>


Government

Regulations

Tech

Media

GOOGL

SNAP

Meta Wants To Fight Back Order Allowing States and Schools To Sue Over Social Media Addiction

<p>Brookline Capital  analyst Kemp Dolliver   downgrades Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) from Buy to Hold.</p>


Downgrades

EYEN

Brookline Capital Downgrades Eyenovia to Hold

ABUS

Barinthus Biotherapeutics shares are trading lower. The company announced data from the ongoing Phase 2b HBV003 clinical trial.

DBGI

Digital Brands Group shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year decline in Q3 revenue.

<p>Citigroup  analyst Keith Horowitz   maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Buy and raises the price target from $50 to $55.</p>


ALLY

Citigroup Maintains Buy on Ally Financial, Raises Price Target to $55

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>TransDigm Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TDG, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for TransDigm Gr.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 26% bullish and 60%, bearish.</p>
<p>Out of all of the special options we uncovered, 12 are puts, for a total amount of $1,689,007, and 3 are calls, for a total amount of $122,970.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $765.0 and $1325.0 for TransDigm Gr, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for TransDigm Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of TransDigm Gr's whale trades within a strike price range from $765.0 to $1325.0 in the last 30 days. </p>
<h3>TransDigm Gr Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731694605_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$31.3</td>
<td>$30.6</td>
<td>$31.3</td>
<td>$1305.00</td>
<td>$356.8K</td>
<td align="right">121</td>
<td align="right">114</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$54.2</td>
<td>$52.0</td>
<td>$53.5</td>
<td>$1250.00</td>
<td>$292.5K</td>
<td align="right">0</td>
<td align="right">83</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$30.7</td>
<td>$29.0</td>
<td>$29.0</td>
<td>$1200.00</td>
<td>$287.1K</td>
<td align="right">4</td>
<td align="right">205</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$26.8</td>
<td>$22.4</td>
<td>$26.0</td>
<td>$1200.00</td>
<td>$252.2K</td>
<td align="right">4</td>
<td align="right">103</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.0</td>
<td>$11.2</td>
<td>$17.0</td>
<td>$1265.00</td>
<td>$170.0K</td>
<td align="right">34</td>
<td align="right">102</td>
</tr>
</tbody>
</table>
</p>
<h3>About TransDigm Gr</h3>
<p>TransDigm manufactures and services a diverse set of specialized parts for commercial and military aircraft. The firm organizes itself in three segments: power and control, airframes, and a small non-aviation segment, which serves mostly off-road vehicles and mining equipment. It operates as an acquisitive holding company that focuses its portfolio on firms that make proprietary aerospace products with substantial aftermarket demand. TransDigm regularly employs financial leverage to amplify its operating results.</p>
<p>Having examined the options trading patterns of TransDigm Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of TransDigm Gr</h3>
<ul>
<li>With a trading volume of 236,246, the price of TDG is up by 1.44%, reaching $1290.0.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for TransDigm Gr</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $1531.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on TransDigm Gr with a target price of $1500.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on TransDigm Gr, which currently sits at a price target of $1563. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest TransDigm Gr options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


TransDigm Gr Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Intuit</strong>.</p>
<p>Looking at options history for Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) we detected 14 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $224,213 and 9, calls, for a total amount of $436,947.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $560.0 to $730.0 for Intuit over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Intuit's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Intuit's significant trades, within a strike price range of $560.0 to $730.0, over the past month.</p>
<h3>Intuit Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731694599_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$5.1</td>
<td>$4.2</td>
<td>$4.8</td>
<td>$730.00</td>
<td>$120.0K</td>
<td align="right">5</td>
<td align="right">451</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$89.7</td>
<td>$87.2</td>
<td>$89.6</td>
<td>$720.00</td>
<td>$71.6K</td>
<td align="right">4</td>
<td align="right">10</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$94.7</td>
<td>$91.5</td>
<td>$94.7</td>
<td>$730.00</td>
<td>$66.2K</td>
<td align="right">9</td>
<td align="right">11</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$144.5</td>
<td>$140.9</td>
<td>$142.0</td>
<td>$560.00</td>
<td>$56.8K</td>
<td align="right">5</td>
<td align="right">2</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$81.7</td>
<td>$80.0</td>
<td>$80.42</td>
<td>$610.00</td>
<td>$56.2K</td>
<td align="right">80</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuit</h3>
<p>Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.</p>
<p>Having examined the options trading patterns of Intuit, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Intuit</h3>
<ul>
<li>Currently trading with a volume of 650,880, the INTU's price is down by -2.25%, now at $685.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>Professional Analyst Ratings for Intuit</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $800.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Intuit, targeting a price of $800. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuit with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


INTU

What the Options Market Tells Us About Intuit

JAGX and GNPX among Health Care movers

XTIA, PSNL and LIDR among mid-day movers

Andean Precious Metals Corp (APM) has gained Wednesday morning, with the stock increasing 888.10% in pre-market trading to 8.3. APM's short-term technical score of 55 indicates that the stock has traded more bullishly over the last month than 55% of stocks on the market. In the Biotechnology industry, which ranks 100 out o

Andean Precious Metals Corp (APM) has risen 888.10% Wednesday In Premarket Trading

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The best <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. </p>



<p>Regulatory hurdles make finding biotech stocks to buy challenging if you don&rsquo;t have the patience to wait it out.</p>



<p>But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That&rsquo;s why it&rsquo;s a good idea to at least consider biotech, and whether they have a spot in your portfolio.</p>



<p>Biotech stocks represent companies involved in the research, development and commercialization of biological-based products that are designed to improve health. These companies can include pharmaceuticals, biotechnology, medical devices, and healthcare services.</p>



<p>While the industry is challenging because of the regulatory approval process and keen competition, biotech stocks do have some significant advantages. </p>



<p>For example, they are relatively immune to economic downturns. Even when the economy does poorly, people and insurance companies will spend money on monthly medications they need to improve their quality of life. </p>



<p>As the population ages, healthcare spending for pharmaceuticals and other medical products will continue to increase.</p>



<p>We&rsquo;re using the Portfolio Grader to find the best biotech stocks to buy in today&rsquo;s market. Each of these stocks gets top grades.</p>



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div><p>Weight loss drugs are one of the most popular trends in the biotech industry right now, with an estimated <a href="https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity">42% of the U.S. population</a> considered obese. That&rsquo;s why the first two companies on our list are top picks, both of them are soaring on the strength of their weight loss medications.</p>



<p>The U.S.-based company in this equation is <strong>Eli Lilly &amp; Co.</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/"><strong>LLY</strong></a>), which markets its obesity drug under the name Zepbound. About 1 in 3 people who took the injectable drug at its highest dose (15 mg) report losing more than 58 pounds over a 72-week period.</p>



<p>The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes. Analysts believe that Zepbound can eventually be worth $25 billion a year in sales, and that Mounjaro sales could jump from $5.2 billion in 2023 to $16 billion in 2024.</p>



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div><p>The European entry into this equation is <strong>Novo Nordisk</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/"><strong>NVO</strong></a>), which has an injectable weight loss drug of its own called Wegovy. Wegovy was approved in 2021 in the U.S. to treat obesity and recently expanded to the U.K.</p>



<p>Expansion came with some growing pains, though. Some pharmacies continue to report shortages, and Novo Nordisk <a href="https://www.novonordisk-us.com/supply-update.html">says</a> its running its manufacturing lines 24 hours a day to try to maintain the supply.</p>



<p>Norvo Nordisk also manufactures the drug Ozempic as a treatment for type 2 diabetes, but doctors have also prescribed it as a treatment for weight loss.</p>



<p>NVO saw <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167013">revenue</a> of $21.4 billion in the fourth quarter, up 31% from the previous year. Profits of $7.7 billion were a 51% increase from the previous year.</p>



<p>NVO stock is up 20% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Corbus Pharmaceuticals (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div><p><strong>Corbus Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/"><strong>CRBP</strong></a>) is a Massachusetts-based drugmaker specializing in oncology treatments. The company has potential drugs in its pipeline to treat solid tumors with antibody drug conjugates and monoclonal antibodies.</p>



<p>The most advanced treatment is treating U.S. patients with metastatic urothelial cancer <a href="https://www.corbuspharma.com/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1">in a trial study</a>.</p>



<p>Corbus also started work on a treatment for obesity and related conditions, although trials for that aren&rsquo;t expected to begin until the fourth quarter of this year.</p>



<p>Corbus doesn&rsquo;t have revenue coming in yet, so it&rsquo;s seeing steep losses &ndash; $8 million in the fourth quarter and $44.6 million for the full year. But that&rsquo;s expected for a biotech stock that has drugs in the pipeline but none yet for sale. You have to be willing to ride it out.</p>



<p>Many investors are. CRBP stock is up more than 500% so far this year as the market reacts to positive developments in the company&rsquo;s clinical trials. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Aptorum Group (APM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/apm-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website for Aptorum Group (APM)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Aptorum Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/apm-stock-quote/"><strong>APM</strong></a>) is a U.K.-based pharmaceutical company developing oncology and infectious diseases treatments. </p>



<p>Its approach includes screening approved drug molecules and using its research platform to seek and develop new treatments and therapies.</p>



<p>The company recently agreed to a <a href="https://www.marketwatch.com/story/aptorum-group-to-merge-with-yoov-group-split-off-legacy-assets-28822b75">reverse merger</a> between its wholly owned subsidiary and <strong>YOOV Group</strong>, specializing in AI techniques to optimize business operations. &nbsp;APM shareholders will own 10% of the combined company after the merger.</p>



<p>Aptorum also plans to split off its legacy business assets into a subsidiary to be called Aptorum Therapeutics.</p>



<p>News of the merger and restructuring turbocharged APM shares, which are now up 264% in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Merck &amp; Co. (MRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-3-300x169.jpg" alt="Merck (MRK) logo outside of corporate building"><div>Source: Atmosphere1 / Shutterstock.com</div></div><p><strong>Merck &amp; Co.</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/"><strong>MRK</strong></a>) is a New Jersey-based pharmaceutical company best known for its Keytruda cancer treatment. Keytruda brought in <a href="https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023">$25 billion</a> in sales in 2023, making it the top-selling drug in the world.</p>



<p>But Merck also has many other drugs on the market, including Gardasil for human papillomavirus; ProQuad, which is a vaccine for measles, mumps, rubella and chickenpox; and Januvia for type 2 diabetes. And that&rsquo;s important, as Merck will lose exclusivity for Keytruda in 2028, making it available for generic substitutes.</p>



<p>Merck expanded that pipeline last month by <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/">completing its acquisition</a> of Harpoon Therapeutics. The company&rsquo;s lead drug candidate treats small cell lung cancer and neuroendocrine tumors.</p>



<p>Earnings for the <a href="https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/">fourth quarter</a> included revenue of $14.6 billion, up 6% from a year ago. The company reported a loss of $1.2 billion and 48 cents per share as part of previously announced charges incurred in its deal with <strong>Daiichi Sankyo</strong> to jointly develop three cancer treatments.</p>



<p>MRK stock is up 16% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Gyre Therapeutics (GYRE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Gyre Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/"><strong>GYRE</strong></a>) is a North Carolina-based biotech company developing treatments for organ fibrosis and inflammatory diseases. </p>



<p>The company completed a Phase 2 trial in China for its treatment of hepatitis B-induced liver fibrosis.</p>



<p>It&rsquo;s now planning a Phase 2 trial for the treatment in the U.S. The drug candidate, Hydronidone, is a structural analog of pirfenidone, which is already approved in the U.S. and China for the treatment of idiopathic pulmonary fibrosis.</p>



<p>The company says there are more than 140 million people who have liver fibrosis from hepatitis B, with no approved therapies on the market. So, its treatment has the potential to be profitable for investors.</p>



<p>Gyre posted full-year revenue in 2023 of $113.5 million, up from $102.3 million in 2022.</p>



<p>GYRE stock is up 330% in the last 12 months, but has been falling so far in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Neurogene (NGNE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div><p><strong>Neurogene</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ngne-stock-quote/"><strong>NGNE</strong></a>) is a biotech company that is developing what it calls EXACT gene therapy technology. </p>



<p>The platform can be used to achieve optimized levels of transgene expression for each drug candidate, which Neurogene says gives it an advantage over traditional gene therapy.</p>



<p>It&rsquo;s currently working with the platform to develop its lead gene therapy candidate for Rett syndrome, which is a disorder seen in children that impairs their ability to walk, eat, speak or breathe.</p>



<p>The company went public just last year in a <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and">reverse merger</a> with cancer drug developer Neoleukin Therapeutics backed by investment firms that put $95 million into the newly formed company. The investment is expected to <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-fourth-quarter-and-full-year-2023-financial">assure Neurogene of funding</a> until the second half of 2026.</p>



<p>That gives it a solid window to develop and get approvals.</p>



<p>NGNE stock is up 95% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<p><em>On the date of publication, Louis Navellier held LLY and NVO. He did not have (either directly or indirectly) any other positions in the securities mentioned in this article.</em></p>



<p><em>The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">7 A-Rated Aggressive Biotech Stocks to Bet On in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

CGC, GENE and HOLO among mid-day movers

Aptorum Group (APM) has released an update. Aptorum Group, a biopharmaceutical company, has reported a decreased net loss of $4.3 million for the f...

Aptorum Group Reports Decreased Annual Loss

Aptorum Group reports FY results

Aptorum Group (APM) has released an update. Aptorum Group Limited has announced an amendment to extend the term of its Merger Agreement with YOOV G...

Aptorum Group Extends Merger Agreement Term

Aptorum Group (APM) has released an update. Aptorum Group Limited announced the resignation of two directors, Dr. Mirko Scherer and Mr. Charles Bat...

Aptorum Group Board Sees Key Resignations

Aptorum Group (APM) has released an update. Aptorum Group has scheduled its 2024 Annual General Meeting for December 10 in Hong Kong, where shareho...

Aptorum Group Announces Key Shareholder Meeting

AILE

AISP

ALRN

ANGH

ANVS

APAC

AQST

BNTC

BPTH

CRBP

EDBL

FEMY

GENE

GNPX

GYRE

HOLO

ICLK

INLX

JAGX

LFCR

LIDR

MIGI

NGNE

NRXP

PSNL

RETO

RLMD

SINT

SWVL

TFFP

THCH

TOON

TRUG

TSHA

WISA

WORX

WULF

XPON

XTIA

XTLB

Press Releases

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Comments

Aptorum Gr

Interés en corto

Aptorum Gr (NASDAQ:APM) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL